COGT - Cogent Biosciences Inc

-

$undefined

N/A

(N/A)

Cogent Biosciences Inc NasdaqGS:COGT Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Location: 275 Wyman Street, Waltham, MA, 02451, United States | Website: https://www.cogentbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

506.9M

Cash

245.7M

Avg Qtr Burn

-55.44M

Short % of Float

21.16%

Insider Ownership

0.16%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details
Advanced systemic mastocytosis (AdvSM)

Phase 2

Data readout

Phase 2

Data readout

CGT4859 (FGFR2 inhibitor) Details
Advanced cholangiocarcinoma

Phase 1

Data readout

IND

Submission